Response of undifferentiated and dedifferentiated endometrial cancer to pembrolizumab: a case report.

IF 2 4区医学 Q3 ONCOLOGY

Anti-Cancer Drugs Pub Date : 2026-10-01 Epub Date: 2026-04-21 DOI:10.1097/CAD.0000000000001824

Peter G Rose, Johanna Kelley, Aaron Petty, Robert Soslow

{"title":"Response of undifferentiated and dedifferentiated endometrial cancer to pembrolizumab: a case report.","authors":"Peter G Rose, Johanna Kelley, Aaron Petty, Robert Soslow","doi":"10.1097/CAD.0000000000001824","DOIUrl":null,"url":null,"abstract":"<p><p>To report our experience with pembrolizumab in undifferentiated and dedifferentiated endometrial cancer. We performed an institutional review board-approved, retrospective study of computerized pharmacy records to identify all patients with undifferentiated and dedifferentiated endometrial carcinomas treated with pembrolizumab. Eleven patients who received pembrolizumab were identified with the following stages: International Federation of Gynecology and Obstetrics stages IC (1), IIC (2), IIIB (2), IIIC2 (2), and IVB (4). One hundred and forty cycles of pembrolizumab were administered. Ten of the 11 patients were mismatch repair (MMR)-deficient. Eight of the patients received pembrolizumab in combination with chemotherapy. Three partial and two complete responses were seen. Both complete responses were seen when pembrolizumab was given with chemotherapy. Four patients were treated in the adjuvant setting with pembrolizumab had no measurable disease and were not evaluable for response but remain disease-free. Two treatment-emergent adverse effects were noted: colitis and hepatitis. Because of the very high rate of MMR deficiency in undifferentiated and dedifferentiated endometrial carcinomas, incorporation of immunotherapy to chemotherapy should strongly be considered in patients with this histologic type in advanced and early-stage disease.</p>","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":"573-577"},"PeriodicalIF":2.0000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-Cancer Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CAD.0000000000001824","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

To report our experience with pembrolizumab in undifferentiated and dedifferentiated endometrial cancer. We performed an institutional review board-approved, retrospective study of computerized pharmacy records to identify all patients with undifferentiated and dedifferentiated endometrial carcinomas treated with pembrolizumab. Eleven patients who received pembrolizumab were identified with the following stages: International Federation of Gynecology and Obstetrics stages IC (1), IIC (2), IIIB (2), IIIC2 (2), and IVB (4). One hundred and forty cycles of pembrolizumab were administered. Ten of the 11 patients were mismatch repair (MMR)-deficient. Eight of the patients received pembrolizumab in combination with chemotherapy. Three partial and two complete responses were seen. Both complete responses were seen when pembrolizumab was given with chemotherapy. Four patients were treated in the adjuvant setting with pembrolizumab had no measurable disease and were not evaluable for response but remain disease-free. Two treatment-emergent adverse effects were noted: colitis and hepatitis. Because of the very high rate of MMR deficiency in undifferentiated and dedifferentiated endometrial carcinomas, incorporation of immunotherapy to chemotherapy should strongly be considered in patients with this histologic type in advanced and early-stage disease.

查看原文本刊更多论文

未分化和去分化子宫内膜癌对派姆单抗的反应：1例报告。

报告我们使用派姆单抗治疗未分化和去分化子宫内膜癌的经验。我们进行了一项机构审查委员会批准的计算机化药房记录的回顾性研究，以确定所有接受派姆单抗治疗的未分化和去分化子宫内膜癌患者。11名接受派姆单抗治疗的患者被确定为以下阶段：国际妇产科联合会分期IC(1)、IIC(2)、IIIB(2)、IIIC2(2)和IVB(4)。给予140个周期的派姆单抗。11例患者中有10例是错配修复（MMR）缺陷。其中8名患者接受了派姆单抗联合化疗。观察到3个部分反应和2个完全反应。当派姆单抗与化疗联合使用时，两种完全缓解都出现了。在辅助治疗中使用派姆单抗的4例患者没有可测量的疾病，也无法评估反应，但仍无疾病。注意到两种治疗出现的不良反应：结肠炎和肝炎。由于未分化和去分化子宫内膜癌的MMR缺乏率非常高，因此在晚期和早期疾病的这种组织学类型的患者中，应强烈考虑将免疫治疗与化疗结合。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anti-Cancer Drugs 医学-药学

CiteScore

3.80

自引率

0.00%

发文量

244

审稿时长

3 months

期刊介绍： Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.